✦ LIBER ✦

Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial

✍ Scribed by Andrew G. Bostom; Myra A. Carpenter; John W. Kusek; Lawrence G. Hunsicker; Marc A. Pfeffer; Andrew S. Levey; Paul F. Jacques; Joyce McKenney

Book ID: 116190547
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 117 KB
Volume: 152
Category: Article
ISSN: 1097-6744
DOI: 10.1016/j.ahj.2006.03.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Baseline Characteristics of Participants

Baseline Characteristics of Participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial

✍ Andrew G. Bostom; Myra A. Carpenter; Lawrence Hunsicker; Paul F. Jacques; John W 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 283 KB

52 Prevalence of CVD Risk Factors and th

52 Prevalence of CVD Risk Factors and their Treatment in Chronic, Stable Kidney Transplant Recipients in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial

✍ Myra A. Carpenter; Andrew Bostom; John W. Kusek; Deborah Adey; Edward Cole; Andr 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 223 KB

Rationale, design, and methods for the T

Rationale, design, and methods for the Transplant-Eligible MAnagement of Congestive Heart Failure (TMAC) trial: A multicenter clinical outcomes trial using nesiritide for TMAC

✍ Mandeep R. Mehra; Ted McCluskey; Mark Barr; Robert C. Bourge; Mariell L. Jessup; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 177 KB

Rationale, design and baseline character

Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: The Heart Outcomes Prevention Evaluation (HOPE)-2 trial

✍ Eva Lonn 📂 Article 📅 2006 🏛 Pulsus Group Inc 🌐 English ⚖ 237 KB

Rationale, design, and baseline characte

Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention)

✍ The ORIGIN Trial Investigators 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 188 KB

Rationale and design of a study to evalu

Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: the IMPROVE trial

✍ Bakris, G L; Ruilope, L; Locatelli, F; Ptaszynska, A; Pieske, B; Raz, I; Voors, 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 115 KB